ArticleNPJ science of food2026
Hydroxytyrosol attenuates obesity-induced myocardial fibrosis by inhibiting NLRP3/CYLD/NOX4 mediated oxidative stress.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hydroxytyrosol (HT), the most bioactive polyphenol in virgin olive oil, has been shown to have cardiometabolic benefits in obese rats, but the underlying mechanism has not been fully elucidated. The aim of this study was to explore the potential driving mechanism in the initiation node of obesity-induced myocardial fibrosis through in vivo and in vitro experiments, and the role of HT in obesity-induced myocardial fibrosis was investigated based on the above mechanisms. The results demonstrated that HT reduced cardiomyocyte oxidative stress and ultimately ameliorated myocardial injury and fibrosis in obese mice by inhibiting NLRP3 inflammasome-dependent pyroptosis, which in turn downregulated the deubiquitinating enzyme cylindromatosis (CYLD), thereby reducing NADPH oxidase (NOX)4 deubiquitination and promoting its degradation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.